Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

Amgen logo
AmgenAMGN
$0.000.0%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$0.000.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0.000.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$0.000.0%
Incyte logo
IncyteINCY
$0.000.0%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 11)
Stockholders’ equity:
Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of March 31, 2026 and December 31, 2025; 137,138 shares issued and outstanding as of March 31, 2026 and December 31, 20252,9312,931
Common stock, $0.001 par value; 545,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 50,167,623 and 48,722,309 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively5049
Additional paid-in capital705,196657,561
Accumulated other comprehensive income (loss)(480)546
Accumulated deficit(220,977)(189,157)
Total stockholders’ equity486,720471,930

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s common stock par value per share?
Oruka Therapeutics, Inc. (ORKA) reported common stock par value per share of $0.00 in Q1 2026.
How has Oruka Therapeutics, Inc.'s common stock par value per share changed year-over-year?
Oruka Therapeutics, Inc.'s common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.

Ask your AI about Oruka Therapeutics, Inc.'s common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude